Search
Press release
Corporate Press
March 12, 2009

Change of Management in Evonik’s Health & Nutrition Business Unit

  • Dr. Ritzert new head of the Exclusive Synthesis & Amino Acids Business Line
  • Dr. Eul new head of the Catalysts Business Line
  • Dr. Hanko will leave the company

Dr. Hans-Josef Ritzert, head of Evonik Industries AG’s Catalysts Business Line, will take over management of the Exclusive Synthesis & Amino Acids Business Line effective April 1, 2009. His predecessor, Dr. Rudolf Hanko, will leave the company on May 1, 2009, to assume the position of CEO at Siegfried Holding, Zofingen, Switzerland, immediately.

To become acquainted with his new function, Dr. Ritzert will hand over management of the Catalysts Business Line to Dr. Wilfried Eul as early as April 1. Eul was responsible for managing Rexim´s business for Pharmaceutical Amino Acids and headed the Asia Region for Exclusive Synthesis & Amino Acids.

Until further notice, Dr. Ritzert will perform Dr. Eul’s job as head of Rexim and regional president.

Dr. Reiner Beste, head of the Health & Nutrition Business Unit, thanks Dr. Hanko for his successful managerial work during the reorganization of Evonik’s Exclusive Synthesis & Amino Acids Business Line. “Using his outstanding expertise, Dr. Hanko decisively shaped the success of the business unit over the last few years. We regret his departure from Evonik and wish him all the best for his future as well as lot of success at his new job.

About Evonik

Evonik Industries is the creative industrial group from Germany which operates in three business areas: Chemicals, Energy and Real Estate. Evonik is a global leader in specialty chemicals, an expert in power generation from hard coal and renewable energies, and one of the largest private residential real estate companies in Germany. Our strengths are creativity, specialization, continuous self-renewal, and reliability. Evonik is active in over 100 countries around the world. In its fiscal year 2007 about 43,000 employees generated sales of about €14.4 billion and an operating profit (EBITDA) of more than €2.2 billion.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.